Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
9.85
-0.27 (-2.67%)
Sep 25, 2026, 4:00 PM EDT - Market closed
Lyell Immunopharma Revenue
Lyell Immunopharma had revenue of $4.00K in the quarter ending June 30, 2026, a decrease of -50.00%. This brings the company's revenue in the last twelve months to $27.00K, down -55.00% year-over-year. In the year 2025, Lyell Immunopharma had annual revenue of $36.00K, down -40.98%.
Revenue (ttm)
$27.00K
Revenue Growth
-55.00%
P/S Ratio
8,939.84
Revenue / Employee
$168
Employees
161
Market Cap
241.38M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 36.00K | -25.00K | -40.98% |
| Dec 31, 2024 | 61.00K | -69.00K | -53.08% |
| Dec 31, 2023 | 130.00K | -84.55M | -99.85% |
| Dec 31, 2022 | 84.68M | 74.03M | 695.15% |
| Dec 31, 2021 | 10.65M | 2.89M | 37.31% |
| Dec 31, 2020 | 7.76M | 7.10M | 1,080.52% |
| Dec 31, 2019 | 657.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| MacroGenics | 175.14M |
| Cue Biopharma | 37.66M |
| Zentalis Pharmaceuticals | 26.87M |
| AC Immune | 21.67M |
| ProQR Therapeutics | 21.05M |
| Keros Therapeutics | 15.01M |
| Pyxis Oncology | 11.04M |
| Camp4 Therapeutics | 4.22M |
LYEL News
- 12 days ago - Lyell Immunopharma Transcript: 2026 Global Healthcare Conference - Transcripts
- 13 days ago - Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference - GlobeNewsWire
- 17 days ago - Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer - GlobeNewsWire
- 7 weeks ago - Lyell Immunopharma reports Q2 net loss ($44.8M) vs. ($42.7M) last year - TheFly
- 7 weeks ago - Lyell Immunopharma Quarterly report: Q2 2026 - Filings
- 7 weeks ago - Lyell Immunopharma Earnings release: Q2 2026 - Filings
- 7 weeks ago - Lyell Immunopharma Slides: Company presentation - Filings
- 7 weeks ago - Lyell Immunopharma initiated with a Buy at Stifel - TheFly